BSX

BOSTON SCIENTIFIC CORP

Healthcare · Medical Devices

$43.88Sep 29, 2026

AI confidence 51% · refreshes every 15s during session

Investment Snapshot

Moderate evidence · 2 sources

Why it matters

BOSTON SCIENTIFIC CORP shows stable business momentum based on AlphaOS pipeline evidence, with mixed management execution.

Why it matters: Revenue +12% YoY in Q1 FY2026.

TrajectoryStable
ExecutionMixed

2 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue +12% YoY in Q1 FY2026
  • REVENUE BEAT

Pipeline evidence · 0d ago

BSX's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on BSX.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q1 2026

Full BSX earnings analysis

Reported figures for BOSTON SCIENTIFIC CORP — research only, not investment advice.

Revenue YoY
+11.6%
EPS YoY
+100.0%

Latest Intelligence

Updated

What happened recently for BOSTON SCIENTIFIC CORP (BSX) — events, not interpretation.

Event
Reported Q1 2026 revenue +12% YoY.
Also
Last session September 29, 2026 at $43.88.
Source
Q1 2026 earnings

Research & analysis only — not investment advice.

Industry & ETF context

Industry blend 53
  • Primary industry Medical Devices scores 53/100 (Recovery cycle, Neutral momentum).
  • Held in 1 ETF(s) — largest weight IHI (4.14%).

Held in ETFsweight · est. sleeve dollars

Investment snapshot

BOSTON SCIENTIFIC CORP

BSX's opportunity score
Upgrade to Premium
Analysis confidence: 51%

BSX's AI investment thesis

Upgrade to Premium for BSX's full multi-agent investment thesis.

Create free account

Free accounts see more of this; Premium sees all of it.

51% confidence

Intelligence layer

Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity

PricesFinancialsFilingsFiling insightsEarningsEarnings AITranscriptsTechnicalOpportunityResearch
  • →Management tone: neutral
  • →Filing signal: Potential insider selling
  • →Held in 1 ETF(s) — largest weight IHI (4.14%).

Latest price

$43.88

Market cap

$63.59B

Profitable

Yes

Revenue $5.20B

Net income

$1.34B

FY Sep 18, 2026

Analyst ratings

Loading Wall Street consensus…

Earnings intelligence

Full earnings center

Loading earnings intelligence…

Technical intelligence

Building technical intelligence snapshot — check back shortly.

Loading market context…

Price & volume

0 trading days

No price history. Sync market data to load charts.

Filing insights

Loading SEC filing intelligence…

Competitive landscape

Recent SEC filings

Filings tab

No filings ingested yet.

BOSTON SCIENTIFIC CORP (BSX)

Healthcare · Medical Devices

Investment Snapshot above is the primary AlphaOS analysis for BOSTON SCIENTIFIC CORP — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Market cap:
$63.59B
Revenue:
$5.20B

BSX earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow BOSTON SCIENTIFIC CORP through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.